Articles On Race Oncology (ASX:RAC)

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Race Oncology (ASX:RAC) has announced that the first patient has been dosed in the Phase 1b/2 trial of Zantrene (bisantrene dihydrochloride) in combination with fludarabine and clofarabine for patients with acute myeloid leukaemia....

Despite a solid start to the day the ASX closed Monday at the same point it closed on Friday. After gaining as much as 0.3% by 11am the ASX 200 closed flat at 7,538 points. The ASX Emerging Companies Index finished slightly higher, by 0.03%...

Summary Nutritional Growth Solutions has entered into a non-exclusive supply agreement to launch Healthy Height® in China. Allegra will explore the new coatings manufacturing process with Swinburne’s ARC Training Centre for SEAM and RM...

The Race Oncology Ltd (ASX: RAC) share price is swinging from losses to gains to losses again. At time of writing, shares in the ASX healthcare company have slipped below yesterday’s closing price, trading down 0.29% at $3.38. We take a lo...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The Race Oncology Ltd (ASX: RAC) share price finished in the red today. The dip came after Race updated the market on its quarterly results before the open. At the closing bell, Race Oncology shares were exchanging hands at $3.44 apiece,...

The ASX200 chalked up another day of gains in Thursday trade, and once again it was resources leading the way. The ASX200 Materials index posted a solid 1.51% gain, and has now risen by at least 1% on five of the last seven trading days. Pr...

After a rough couple of days, local stocks got back in the saddle on Wednesday as most large cap sectors finished in positive territory. There was no clear standout on the day, with resources and materials both finishing more than 1% higher...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Most ASX large cap sectors finished in the red today, in a topsy-turvy session which saw the ASX200 fall sharply at the open then claw back ground, before losing steam into the close of trade. Yesterday’s rotation out of large cap mining &a...

Healthcare is a constantly changing industry in which you may be asking yourself if your investments are up to date. While the healthcare sector underperformed the S&P/ASX 200 Index (ASX: XJO) in FY21, there were still some ASX-listed...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

In FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over 390 per cent and made an average gain of 821 per cent. Stockhead has compiled a list (see below) of the 100 best performing ASX stocks base...

Plenty of action on the biotech front today has provided ASX investors with some mouth-watering gains. Suda Pharma (ASX:SUD) led the pack, popping by as much as 44 per cent after announcing an oversubscribed $3.65 million capital raise. The...

The ASX has gained nearly 1.5 per cent per cent today, rebounding from a big Monday selloff. Once again the local bourse followed Wall Street – which has seemingly put concerns over interest rates to the side for now. The ASX 200 closed 1.4...

ShareCafeHidden Gems Webinar Recap: RAC, IMU, AUA & BRN Catch up on the full webinar with presentations from Race Oncology (ASX:RAC), Imugene (ASX:IMU), Auderea (ASX:AUA) & Brainchip (ASX: BRN). Hidden Gems Webinar Recap: RAC, IM...

ShareCafeA precision oncology company Race Oncology (ASX: RAC) – Hidden Gems Webinar. Presenter – Daniel Tillett – Chief Scientific Officer & Executive Director – Race Oncology is a precision oncology company with a Phase II/III cancer...

Summary Race Oncology has entered into an agreement with Trialog Clinical Trials to support its Phase 2 Acute Myeloid Leukemia (AML) trial. Trialog Clinical Trials will supply trial drugs and offer other clinical services to Race Oncol...

There’s no two ways about it, melanoma kills, especially here in Australia. We have one of the highest rates of melanoma in the world, and melanoma is often referred to as ‘Australia’s national cancer’. Around 16,000 Australians are diagnos...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The Race Oncology Ltd (ASX: RAC) share price is falling today after the pharmaceutical company announced a contract award for a leukemia trial. Race Oncology has signed up a leading Israeli company to supply drugs and provide other clinica...

The Race Oncology Ltd (ASX: RAC) share price has been a positive performer on Wednesday. In morning trade, the precision oncology company’s shares are up 3% to $3.70. This latest gain means the Race Oncology share price is now up 99% in 20...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Risk on sentiment returned to the ASX following yesterday’s 1.9 per cent drop. The ASX 200 closed 1.27 per cent higher at 7,020 points while the ASX Emerging Companies Index closed 0.78 per cent higher at 2,101. The rebound was led by tech...

Race Oncology (ASX:RAC) has announced the appointment of Professor Michael Kelso as its principal scientist.

Race Oncology (ASX:RAC) has announced that a team of researchers have identified a number of clinically translatable drug combinations that showed synergy with Bisantrene when tested in Acute Myeloid Leukaemia cells.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Race Oncology (ASX:RAC) says it has received binding commitments to raise $5.4 million before costs in an oversubscribed equity placement to new and existing institutional and sophisticated investors.

The Cancer fighting biotech company Race Oncology Ltd [ASX:RAC] share price is up 4.23% today. Rising higher after coming out of trading halt, and announcing the successful completion of a share placement... The post Race Oncology Share Pr...

Summary The ASX 200 crosses 7100 mark, its 14-month highest level since the coronavirus pandemic-led sell-off triggered in February last year. The market witnessed broad-based rally, with nine of 11 sectors trading in green. Nearmap s...

Summary Neurotech International has commenced Phase I/II open-label clinical trial in children having Autism Spectrum Disorder. Multinational pharmaceutical company AFT Pharmaceuticals disclosed the extension of licensing of Maxigesic®...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.75% to 7,120.3 points. Four ASX shares that are climbing more than most today are listed bel...

The Race Oncology Ltd (ASX: RAC) share price is gaining today, up 5% in late morning trade. The ASX healthcare share entered a trading halt on Monday prior to disclosing the details of a capital raising, which it released this morning. Rac...

On a day the ASX finished nearly 0.5 per cent up, tech stood alone in the red losing more than 2 per cent. The ASX 200 closed 0.56 per cent up at 7,068 points and the ASX Emerging Companies Index rose 0.41 per cent closing at 2,111 points....

Today we will take a look at why we like Race Oncology (ASX RAC). Race Oncology (ASX RAC) is a precision oncology company with a phase II/III cancer drug called Bisantrene. The aim of the company is to build value in Bisantrene through proo...

After gaining 0.5 per cent in the first hour of trade the ASX only finished slightly upwards. The ASX 200 closed at 7,029 points, which was 0.04 per cent higher than Friday. Small caps had a worse day – the ASX Emerging Companies Index clos...

Race Oncology Ltd (ASX: RAC) shares are in a trading halt today as the company seeks to raise an undisclosed amount of capital. At Friday’s close, the Race Oncology share price was trading at $3.07 after significant falls over the past wee...

Summary 5G Networks reported robust growth across all three core products in Q3 FY21 and witnessed a growing demand for the 5GN Voice Bridge One Microsoft Teams product. JB Hi-Fi witnessed double-digit sales growth in two of its three...

Summary Oventus Medical witnessed growth in booked revenue and acceleration in telehealth bookings in Q3 FY21. ECS Botanics Holdings’ March 2021 quarter was action-packed with a major acquisition and multiple supply agreements. Despit...

Summary Race Oncology Limited has entered into a collaboration for the preclinical study of its cancer drug Bisantrene in heart safety. Advanced Human Imaging has executed a Binding Heads of Agreement for the proposed acquisition of Ph...

The Race Oncology Ltd (ASX: RAC) share price is climbing today after an update from the Aussie healthcare company. Why is the Race Oncology share price climbing? Race Oncology announced that it has entered into a collaborative preclinical...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

Race Oncology (ASX:RAC) has announced the appointment of Dr David Fuller as its chief medical officer.

It was another day in the green for the ASX as it edged closer to surpassing the record high it reached immediately prior to COVID-19. The ASX 200 rose 0.51 per cent, closing at 7,058 points while the ASX Emerging Companies Index rose 0.75...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and edging slightly lower. At the time of writing, the benchmark index is down a few points to 7,020 points. Four ASX shares that are not letting that hold them back a...

The Race Oncology Ltd (ASX: RAC) share price has been a very strong performer on Thursday. In morning trade, the precision oncology company’s shares are up 10% to $3.38. Why is the Race Oncology share price storming higher? Investors have...

Another day, another IPO – today the new listee was biotech Island Pharmaceuticals (ASX:ILA). Island Pharmaceuticals is one of the few biotechs fighting mosquito diseases, particularly dengue fever. Its flagship drug ISLA-101 was originally...

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...